Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson. Discuss the data presented at ASCO 2024 on the RELATIVITY-047 study of nivolumab plus relatlimab vs ...

Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced primary results from the Phase 2/3 RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of ...

RELATIVITY-047, a global, randomized, double-blind, phase II/III study, met its primary endpoint of progression-free survival (PFS). Relatlimab and nivolumab (RELA + NIVO) as a fixed-dose combination ...

Please provide your email address to receive an email when new articles are posted on . The addition of relatlimab to nivolumab conferred a significant PFS benefit among treatment-naive patients with ...

(RTTNews) - Bristol Myers Squibb (BMY) today announced that primary endpoint was met in the phase II/III Relativity-047 study, a trial evaluating a fixed dose combination of company's anti-LAG-3 ...

Please provide your email address to receive an email when new articles are posted on . Relatlimab plus nivolumab continued to demonstrate a PFS benefit compared with nivolumab alone for patients with ...

For untreated advanced melanoma, the fixed-dose combination of relatlimab and nivolumab is a "game changer that we have been waiting 10 years for," Hussein Tawbi, MD, PhD, University of Texas MD ...

Relatlimab plus Opdivo improved progression-free survival in patients with untreated, advanced melanoma, and tended to have fewer side effects than other regimens used in this patient population.

Erratum: Randomized Comparison of Intensified Six-Drug Versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue ...